[Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?].
This retrospective study evaluated the prognostic value of the initial or secondary status of pT1G3 bladder tumours. Between 1990 and 2000, 93 patients presented with T1G3 bladder tumour. Seventy-five patients, 54 with initial T1G3 and 21 with secondary T1G3, with no history of invasive bladder tumour, were included in the study. Seventy-two per cent were treated by intravesical BCG. No patient received maintenance therapy. The median follow-up was 53 months (range: 2 to 285 months). On univariate analysis, a significant difference of overall survival was observed in favour of secondary T1G3 tumours compared to initial T1G3 tumours (p < 0.003), while no difference was observed for recurrence, progression and specific survival. This difference was no longer significant on multivariate analysis, but BCG therapy and smoking were significantly correlated with overall and specific mortality. BCG was also correlated with risk of progression. Patients with a secondary T1G3 tumour had a better overall survival. This difference was no longer significant when other prognostic factors were taken into account.